Investigating Polypharmacology through Targeting Known Human Neutrophil Elastase Inhibitors to Proteinase 3

Area of Science:

• Biochemistry and Pharmacology
• Drug Discovery and Development

Background:

• Human neutrophil elastase (HNE) and Proteinase 3 (PR3) are serine proteases implicated in various inflammatory diseases.
• Current therapeutic strategies often focus on single targets, limiting efficacy in complex diseases.
• Polypharmacology, targeting multiple enzymes with a single agent, offers a promising approach for enhanced therapeutic outcomes.

Purpose of the Study:

• To evaluate the polypharmacological potential of a dihydropyrimidinone scaffold.
• To assess the scaffold's efficacy in inhibiting both human neutrophil elastase (HNE) and Proteinase 3 (PR3).
• To explore the potential of this scaffold for treating cardiopulmonary diseases, including chronic obstructive pulmonary disease (COPD).

Main Methods:

• Utilized multisite λ-dynamics (MSλD) to analyze molecular interactions.
• Performed in vitro IC50 assays to quantify enzyme inhibition.
• Investigated the binding affinities of the dihydropyrimidinone scaffold against HNE and PR3.

Main Results:

• The dihydropyrimidinone scaffold demonstrated inhibitory activity against both HNE and PR3.
• Observed affinities suggest a viable starting point for dual-targeting drug development.
• The scaffold's polypharmacological profile indicates potential for enhanced therapeutic effects.

Conclusions:

• The dihydropyrimidinone scaffold exhibits potential for polypharmacological inhibition of HNE and PR3.
• This scaffold represents a promising starting point for developing novel therapeutics for cardiopulmonary diseases.
• Dual targeting of HNE and PR3 may offer improved treatment strategies for conditions like COPD.